Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-08046054 · 2 trials · 11 indications
Overall survival defined as the time from the date of randomization to the date of death due to any cause.
Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
| Arm | Type | Description |
|---|---|---|
| PF-08046054 monotherapy | EXPERIMENTAL | PF-08046054 monotherapy |
| Docetaxel monotherapy | ACTIVE_COMPARATOR | Docetaxel monotherapy |
| PF-08046054 Combination Therapy | EXPERIMENTAL | PF-08046054 + pembrolizumab |
| Name | Type | Description |
|---|---|---|
| PF-08046054 | DRUG | Antibody Drug Conjugate Participants will receive PF-08046054, administered as an IV infusion. |
| Docetaxel monotherapy | DRUG | Participants will receive Docetaxel, administered as an IV infusion. |
| pembrolizumab | DRUG | 200 mg once every 3 weeks given into the vein (IV; intravenously) |
Inclusion Criteria * Histologically or cytologically confirmed diagnosis of NSCLC with locally advanced, unresectable Stage IIIB or IIIC not eligible for definitive chemoradiotherapy or metastatic (Stage IV: M1a, M1b, or M1c) disease per the American Joint Committee on Cancer (AJCC) Staging Manual,...
PF-08046054 is an investigational small molecule being developed for oncology indications, including non-small-cell lung cancer, squamous cell carcinoma of the head and neck, esophageal squamous cell carcinoma, triple negative breast neoplasms, gastric cancer, endometrial cancer, pancreatic adenocarcinoma, and hepatocellular carcinoma. It is currently in Phase 1 clinical development.
PF-08046054 targets PD-L1, a protein involved in immune checkpoint regulation. By targeting PD-L1, the drug is designed to modulate the immune response against cancer cells. This mechanism is being studied in the context of advanced solid tumors, including non-small-cell lung cancer.
PF-08046054 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical trials for multiple oncology indications.
PF-08046054 is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is studying the drug in advanced solid tumors, with additional trials planned for later phases.
PF-08046054 is being studied in a Phase 1 trial (NCT05208762) for advanced solid tumors, enrolling 714 participants across multiple countries. A Phase 3 trial (NCT07144280) is also recruiting to compare PF-08046054 versus docetaxel in previously-treated PD-L1 positive non-small-cell lung cancer, with an enrollment target of 680 participants.
Yes, PF-08046054 is also known as SGN-PDL1V. Both names refer to the same investigational drug being developed by Pfizer. The Phase 1 and Phase 3 clinical trials listed for PF-08046054 use both names in their official titles, confirming they are the same compound.